GLP-2
Typical Dosing Protocols (Research/Compounded Use Only) – Tirzepatide
Common protocol: 2.5 mg subcutaneously once weekly for the first 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated (e.g., to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or up to 15 mg weekly). Maintenance doses are typically 5–15 mg once weekly depending on response and goals (weight management or metabolic support).
Other reported ranges: 2.5–15 mg once weekly; some protocols start lower (1.5–2.5 mg) or titrate more slowly to minimize side effects. Titration is gradual over 4+ weeks per step; long-term use is common rather than short cycles, with ongoing monitoring.
Reconstitution example (for a typical 10 mg vial): Add 1 mL bacteriostatic water (yielding 10 mg/mL).
2.5 mg = 0.25 mL (25 units on U-100 insulin syringe)
5 mg = 0.50 mL (50 units)
7.5 mg = 0.75 mL (75 units)
10 mg = 1.0 mL (100 units)
Administration: Subcutaneous injection (abdomen, thigh, or upper arm); any time of day, with or without food. Rotate injection sites weekly.
Dosing is highly individualized based on goals and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
Key Potential Benefits of Tirzepatide
1. Significant Weight Loss and Body Composition Improvement
Produces substantial, dose-dependent weight reduction (often 15–20%+ of body weight in trials).
Reduces fat mass while helping preserve lean muscle.
Supports long-term weight maintenance when continued.
2. Effective Glycemic Control in Type 2 Diabetes
Lowers HbA1c by 1.87–2.59% (20–28 mmol/mol) on average.
Improves insulin sensitivity and glucose-dependent insulin secretion.
Reduces fasting and postprandial blood glucose levels.
3. Appetite Suppression and Satiety Enhancement
Decreases hunger and food intake through dual GLP-1 and GIP receptor activation.
Increases feelings of fullness and reduces cravings.
Slows gastric emptying for better portion control.
4. Cardiometabolic Health Improvements
Lowers blood pressure, triglycerides, and LDL cholesterol.
Improves overall lipid profile and cardiovascular risk markers.
Supports better metabolic health and reduced visceral adiposity.
5. Additional Systemic Benefits
May improve obstructive sleep apnea symptoms.
Enhances energy levels and quality of life through better metabolic function.
Shows promise for broader applications in obesity-related conditions.
These benefits are well-documented in large Phase 3 clinical trials (SURPASS and SURMOUNT programs). Tirzepatide is a dual GIP/GLP-1 receptor agonist.
